title: Involvement of formyl-peptide-receptor-like-1 and phospholipase D in the internalization and signal transduction of amyloid beta 1-42 in glial cells.
abstract: Recent studies suggest that the formyl-peptide-receptor-like-1 (FPRL1) plays an essential role in the inflammatory responses of host defense mechanisms and neurodegenerative disorders such as Alzheimer's disease (AD). We therefore analyzed whether amyloid beta1-42 (Abeta1-42) increased the activity of phospholipase D (PLD) via FPRL1, which is an enzyme involved in the secretion, endocytosis and receptor signaling. PLD activity was determined using a transphosphatidylation assay. The internalization of Abeta1-42 via FPRL1 was visualized using fluorescence microscopy and quantified by ELISA (Enzyme Linked Immunosorbent Assay). Determining receptor activity by extracellular-signal regulated kinases 1/2 (ERK1/2) phosphorylation and cAMP level measurement verified the Abeta1-42-induced activation of FPRL1. We were able to show that Abeta1-42 is rapidly internalized via FPRL1 in astrocytes and microglia. PLD was additionally activated by Abeta1-42 and via FPRL1 in rat glial cells. Furthermore, the ERK1/2 phosphorylation by FPRL1 agonists was dependent on the PLD product phosphatidic acid (PA). Together, these data suggest that PLD plays an important role in the regulation of Abeta1-42-induced endocytosis and FPRL1 receptor signaling.
authors: Department of Anatomy and Cell Biology, University Hospital RWTH Aachen, Wendlingweg 2, 52074 Aachen, Germany. lbrandenburg@ukaachen.de
authors: L-O
authors: LO
authors: Brandenburg
authors: M
authors: M
authors: Konrad
authors: C
authors: C
authors: Wruck
authors: T
authors: T
authors: Koch
authors: T
authors: T
authors: Pufe
authors: R
authors: R
authors: Lucius
mesh_terms: D016229:Amyloid beta-Peptides / Q000819:agonists / Q000378:metabolism* / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001921:Brain / Q000166:cytology; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism*; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000819:agonists / Q000378:metabolism* / Q000494:pharmacology; D010739:Phospholipase D / Q000378:metabolism*; D051381:Rats; D044042:Receptors, Formyl Peptide / Q000819:agonists / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors; D020002:tert-Butyl Alcohol / Q000494:pharmacology
chemical_list: D016229:Amyloid beta-Peptides; C469986:FPR1 protein, human; D009842:Oligopeptides; D010446:Peptide Fragments; D044042:Receptors, Formyl Peptide; C075222:amyloid beta-protein (1-42); C509690:tryptophyl-arginyl-tryptophyl-tryptophyl-tryptophyl-tryptophanamide; D000242:Cyclic AMP; D048052:Mitogen-Activated Protein Kinase 3; D020929:Mitogen-Activated Protein Kinase Kinases; D010739:Phospholipase D; D020002:tert-Butyl Alcohol